MARKET

SAVAW

Cassava Sciences, Inc. Warrants
SAVAW
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-
-
0.0092
-
CASSAVA SCIENCES INC - ON DEC 15, FDA PLACES FULL CLINICAL HOLD ON CASSAVA'S TRIAL - SEC FILING
Reuters · 16h ago
CASSAVA SCIENCES: NOT EXPECTED TO INITIATE PROOF-OF-CONCEPT CLINICAL TRIAL FOR SIMUFILAM IN TSC-RELATED EPILEPSY IN H1 2026 AS PREVIOUSLY DISCLOSED
Reuters · 16h ago
FDA Puts Cassava Sciences Simufilam Trial on Full Clinical Hold
Reuters · 16h ago
Cassava Sciences Awards 2025 Cash Bonuses to Top Executives
Reuters · 1d ago
CASSAVA SCIENCES INC - EXPECTS FORMAL LETTER FROM FDA DETAILING ISSUES ON CLINICAL TRIAL FOR SIMUFILAM - SEC FILING
Reuters · 12/03 11:28
Cassava Sciences Faces FDA Request for More Data on Simufilam Epilepsy Trial
Reuters · 12/03 11:27
Director Robert Eugene Anderson Jr. acquires common shares of Cassava Sciences Inc
Reuters · 11/25 21:06
Cassava Sciences CEO Richard Barry Acquires Common Shares
Reuters · 11/24 21:02
More

Webull offers Cassava Sciences, Inc. Warrants stock information, including NASDAQ: SAVAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAVAW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SAVAW stock methods without spending real money on the virtual paper trading platform.